Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02270242 · ClinicalTrials.gov registry record · Phase 4
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 4
- Development phase
- 9,006
- Enrollment target
NCT02270242 is a Phase 4 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 9,006 participants.
The verdict
NCT02270242, a Phase 4 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9,006 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the use of ticagrelor alone versus ticagrelor and aspirin together. Both ticagrelor and aspirin stop platelets from sticking together and forming a blood clot that could block blood flow to the heart. This study will look to determine the effectiveness and safety of ticagrelor alone, compared to ticagrelor plus aspirin in reducing clinically relevant bleeding and in reducing ischemic adverse events among high-risk patients who have had a percutaneous intervention with at least one drug-eluting stent. A patient is considered high-risk if they meet certain clinical and/or anatomic criteria. Up to 9000 subjects will be enrolled at the time of their index PCI. Subjects meeting randomization eligibility criteria at 3 months post enrollment will be randomized to either ticagrelor plus aspirin or ticagrelor plus placebo for an additional 12 months. Follow-up clinic visits will be performed at 3 months, 9 months and 15 months post enrollment.
Interventions
- DRUG Placebo
- DRUG Aspirin
- DRUG ticagrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,006 participants |
| Start Date | 2015-07 |
| Est. Completion | 2019-07-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02270242
The ClinicalTrials.gov registry entry for NCT02270242 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 9,006 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02270242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02270242 about?
NCT02270242 is a clinical study titled "Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention". The purpose of this study is to compare the use of ticagrelor alone versus ticagrelor and aspirin together. Both ticagrelor and aspirin stop platelets from sticking together and forming a blood clot that could block blood flow to the heart. This study will look to determine the effectiveness and saf...
What is the current status of trial NCT02270242?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9,006 participants. The study started on 2015-07. Estimated completion is 2019-07-10.
What interventions are being tested in trial NCT02270242?
The interventions under investigation include: Placebo (DRUG), Aspirin (DRUG), ticagrelor (DRUG).
Who is sponsoring clinical trial NCT02270242?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.